North American Report

Advanced Hepatocellular Carcinoma Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Advanced Hepatocellular Carcinoma Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

January 23
17:16 2023
Advanced Hepatocellular Carcinoma Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Advanced Hepatocellular Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including Advanced Hepatocellular Carcinoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Advanced Hepatocellular Carcinoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Advanced Hepatocellular Carcinoma clinical trials studies, Advanced Hepatocellular Carcinoma NDA approvals (if any), and product development activities comprising the technology, Advanced Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report

 

  • DelveInsight’s Advanced Hepatocellular Carcinoma Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Hepatocellular Carcinoma.

 

  • The leading Advanced Hepatocellular Carcinoma Companies includes CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.

 

  • Promising Advanced Hepatocellular Carcinoma Pipeline Therapies includes Enzalutamide, ABT-869, IBI308 200mg, Pembrolizumab/Quavonlimab, Lenvatinib, Cabozantinib, Sorafenib, INC280, Apatinib, Octreotide, and others.

 

  • The Advanced Hepatocellular Carcinoma Companies and academics are working to assess challenges and seek opportunities that could influence Advanced Hepatocellular Carcinoma R&D. The Advanced Hepatocellular Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Advanced Hepatocellular Carcinoma.

 

To explore more information on the latest breakthroughs in the Advanced Hepatocellular Carcinoma Pipeline treatment landscape of the report, click here @ Advanced Hepatocellular Carcinoma Pipeline Outlook

 

Advanced Hepatocellular Carcinoma Overview

 

Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause of death by cancer each year. Unfortunately, considerable number of patients are diagnosed at advanced stage unsuitable for surgery or local treatment with poor prognosis and a median overall survival (OS) of about 6 months. Molecular targeted therapies have demonstrated promising efficacy in the management of cancer. Advanced HCC has experienced the most relevant advancements in research in HCC lately. Advanced HCC was defined as a liver tumor not eligible for local therapies given the extent of disease or liver tumors that recurred after local therapies.

 

Advanced Hepatocellular Carcinoma Emerging Drugs Profile 

 

Tivozanib : AVEO Oncology

FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

 

Nofazinlimab: CStone Pharmaceuticals

CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 . CS1003 is also unique in that it can simultaneously recognize human and mouse PD-1, which allows fast pre-clinical proof of concept for CS1003 in combination with novel targeted therapies using syngeneic mouse tumor models. Currently, the drug is being developed in Phase III stage of development for the treatment of advanced hepatocellular carcinoma.

 

ECT 204: Eureka Therapeutics

ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Sintilimab: Eli Lilly and Company/Innovent

Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Currently, the drug is being developed in Phase I stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

 

Request a sample and discover the recent advances in advanced hepatocellular carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Hepatocellular Carcinoma Treatment Landscape

 

Advanced Hepatocellular Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Advanced Hepatocellular Carcinoma. The companies which have their Advanced Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, CStone Pharmaceuticals.

 

Advanced Hepatocellular Carcinoma Phases

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

For further information, refer to the detailed Advanced Hepatocellular Unmet Needs, Advanced Hepatocellular Market Drivers, and Market Barriers, click here for Advanced Hepatocellular Ongoing Clinical Trial Analysis

 

Scope of the Advanced Hepatocellular Carcinoma Pipeline Report

 

  • Coverage- Global

 

  • Advanced Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.

 

  • Advanced Hepatocellular Carcinoma Pipeline Therapies- Enzalutamide, ABT-869, IBI308 200mg, Pembrolizumab/Quavonlimab, Lenvatinib, Cabozantinib, Sorafenib, INC280, Apatinib, Octreotide, and others.

 

  • Advanced Hepatocellular Carcinoma Pipeline Segmentation: Phases, Product Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Advanced Hepatocellular Carcinoma Market Drivers and Advanced Hepatocellular Carcinoma Market Barriers, click here @ Advanced Hepatocellular Carcinoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Advanced Hepatocellular Carcinoma Executive Summary
  3. Advanced Hepatocellular Carcinoma: Overview
  4. Advanced Hepatocellular Carcinoma Pipeline Therapeutics
  5. Advanced Hepatocellular Carcinoma Pipeline Therapeutic Assessment
  6. Advanced Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug name : Company Name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. Nofazinlimab: CStone Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase I/II)
  14. Tivozanib : AVEO Oncology
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Hepatocellular Carcinoma Key Companies
  21. Advanced Hepatocellular Carcinoma Key Products
  22. Advanced Hepatocellular Carcinoma – Unmet Needs
  23. Advanced Hepatocellular Carcinoma – Market Drivers and Barriers
  24. Advanced Hepatocellular Carcinoma – Future Perspectives and Conclusion
  25. Advanced Hepatocellular Carcinoma Analyst Views
  26. Advanced Hepatocellular Carcinoma Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Advanced Hepatocellular Carcinoma Mergers and acquisitions, Advanced Hepatocellular Carcinoma licensing activities @ Advanced Hepatocellular Carcinoma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services